secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2024-12-23T23:59:59+00:00
Accession:  0000950170-24-139633
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma expands at-the-market equity facility with Jefferies after exhausting prior $65M capacity
--------------------------------------------------------------------------------

- On Dec 23, 2024, amended Open Market Sale Agreement with Jefferies to allow additional common stock sales.
- Prior aggregate offering amount of $65M under the Sales Agreement was fully sold as of the amendment date.
- New shares may be sold at the market; amount governed by prospectus supplement filed December 23, 2024.
- Original terms and conditions of the Sales Agreement remain unchanged; Jefferies will use commercially reasonable efforts.
- Issuance will be made under effective registration statement on Form S-3 (File No. 333-275455).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017024139633/0000950170-24-139633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017024139633/atyr-20241224.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-139633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer